SRR12202457
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.480
- OXIDATIVE_PHOSPHORYLATION+0.370
- TGF_BETA_SIGNALING+0.350
- PANCREAS_BETA_CELLS+0.230
- UV_RESPONSE_DN+0.200
- MYC_TARGETS_V1+0.140
- ADIPOGENESIS+0.130
- ANDROGEN_RESPONSE+0.110
- UNFOLDED_PROTEIN_RESPONSE+0.100
- HEME_METABOLISM+0.050
Top 10 suppressed
- E2F_TARGETS-0.480
- G2M_CHECKPOINT-0.480
- IL6_JAK_STAT3_SIGNALING-0.350
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.340
- HEDGEHOG_SIGNALING-0.330
- INFLAMMATORY_RESPONSE-0.300
- MYOGENESIS-0.300
- CHOLESTEROL_HOMEOSTASIS-0.280
- MITOTIC_SPINDLE-0.270
- APICAL_SURFACE-0.260
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1516042 | — | — | 0.862 |
| 2 | DRR168548 | — | — | 0.832 |
| 3 | MNG427 | — | — | 0.820 |
| 4 | SRR23303735 | — | — | 0.817 |
| 5 | BS_Z7PKVY9J | Med | Medulloblastoma | 0.816 |
| 6 | MNG32 | — | — | 0.801 |
| 7 | MDT-AP-0044 | Med | Medulloblastoma | 0.788 |
| 8 | SRR8943006 | — | — | 0.784 |
| 9 | TCGA-D8-A1JN-01A-11R-A13Q-07 | — | C | 0.783 |
| 10 | SRR12202449 | — | — | 0.782 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.480 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.370 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.350 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.230 | Cobimetinib | — uncovered |
| UV_RESPONSE_DN | 0.200 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.140 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.130 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.110 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.100 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.050 | Temsirolimus | — uncovered |
| NOTCH_SIGNALING | 0.050 | Inavolisib | — uncovered |
| APOPTOSIS | 0.010 | Idelalisib | — uncovered |